Alcobra Ltd. to Release Fourth Quarter and Fiscal Year 2015 Financial Results and Host Corporate Update Conference Call & Webcast on February 17

TEL AVIV, Israel, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2015 before the market open, and will host a corporate update conference call and webcast on Wednesday, February 17 at 8:30 am Eastern Time.

Conference Call & Webcast
Wednesday, February 17, 2016 @ 8:30am Eastern Time
Replays available through March 2, 2016

About Alcobra

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website,, the content of which is not incorporated herein by reference.

U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661

Source:Alcobra Ltd.